78325
document
A comparison of propranolol and nadolol pharmacokinetics and clinical effects in thyrotoxicosis . For a comparison of propranolol and nadolol pharmacokinetics and clinical effects , 20 newly diagnosed patients with thyrotoxicosis were randomly selected to receive as sole therapy , either propranolol , 40 mg every 6 hours for 14 days , or nadolol , 80 mg each morning for 14 days . The study was repeated when the patients were in the euthyroid state . There was a similar and highly significant degree of beta blockade and amelioration of symptoms of thyrotoxicosis at the end of the dosage interval ( trough ) , i.e. , 24 hours after nadolol or 6 to 8 hours after propranolol . Trough and peak serum levels of propranolol were significantly lower when the patients were in a thyrotoxic state than when they were in a euthyroid state , whereas the pharmacokinetics of nadolol were not appreciably altered by thyrotoxicosis . In thyrotoxicosis , trough levels of propranolol and nadolol were significantly inversely correlated with derived creatinine clearance values . In the symptomatic treatment of thyrotoxicosis , nadolol , a once-daily nonmetabolized beta blocker , has certain advantages compared with propranolol . It is preferred by patients , is more convenient , and probably aids compliance .
78326
Intervention_Pharmacological
propranolol
78327
Intervention_Pharmacological
nadolol pharmacokinetics
78328
Intervention_Pharmacological
propranolol
78329
Intervention_Pharmacological
nadolol
78330
Intervention_Pharmacological
propranolol
78331
Intervention_Pharmacological
nadolol
78332
Intervention_Pharmacological
nadolol
78333
Intervention_Pharmacological
propranolol
78334
Intervention_Pharmacological
propranolol
78335
Intervention_Pharmacological
propranolol
78336
Intervention_Pharmacological
nadolol
78337
Intervention_Pharmacological
nadolol
78338
Intervention_Pharmacological
nonmetabolized beta blocker
78339
Intervention_Pharmacological
propranolol
78340
Outcome_Physical
pharmacokinetics
78341
Outcome_Physical
clinical effects
78342
Outcome_Physical
thyrotoxicosis
78343
Outcome_Physical
pharmacokinetics
78344
Outcome_Physical
clinical effects
78345
Outcome_Physical
degree of beta blockade
78346
Outcome_Other
and
78347
Outcome_Physical
amelioration of symptoms
78348
Outcome_Other
of thyrotoxicosis
78349
Outcome_Physical
Trough and peak serum levels of propranolol
78350
Outcome_Physical
pharmacokinetics
78351
Outcome_Physical
trough levels of propranolol and nadolol
78352
Outcome_Other
derived
78353
Outcome_Physical
creatinine clearance values
78354
Outcome_Physical
thyrotoxicosis
78355
Outcome_Mental
compliance
78356
Participant_Condition
thyrotoxicosis .
78357
Participant_Condition
20 newly diagnosed patients with thyrotoxicosis
78358
Participant_Condition
symptomatic treatment of thyrotoxicosis